To get FDA approval for Zepbound , Eli Lilly had to prove the drug was safe, effective, and consistently manufactured through large-scale clinical trials (the SURMOUNT program)
Chen B, Xie G, Lin Y, et al
Compare this to a 10 mg/mL concentration where 0.5 mg is only 5 units, nearly impossible to measure accurately

Nabiximols is not a substitute for standard bladder, sleep, or mobility care, and this meta-analysis does not suggest otherwise.For real-world care, the practical filter is: is the patient already an appropriate spasticity candidate, and if so, is it reasonable to watch these other domains more closely during routine follow-up.Lens takeawayThe paper upgrades the conversation about possible added benefits without changing the fundamentals of standard MS symptom management.What Better Evidence Needs to Do NextThe next step is randomized, adequately powered trials that treat bladder function, sleep disruption, spasm quality, and gait as primary rather than secondary outcomes, with predefined endpoints separate from spasticity response.Researchers also need clearer heterogeneity reporting and a transparent account of why 24 of the 49 eligible articles did not contribute to the pooled statistical analysis, since that detail directly affects how representative the summary effects are.Until that work is done, this meta-analysis is best understood as a well-organized rationale for funding and designing the next generation of nabiximols trials focused specifically on these non-spasticity outcomes.Lens takeawayThe paper earns targeted follow-up research on these specific secondary outcomes

If the product source cannot provide credible testing and handling information, the dosage number becomes even less meaningful